http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2002520335-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-101 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-1024 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-117 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-103 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate | 1999-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2002-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2002520335-A |
| titleOfInvention | Dolastatin 15 derivative |
| abstract | (57) [Summary]nThe compounds of the present invention are cell growth inhibitors, and include the peptide of formula (I): ABDEFG and salts thereof. Here, A, D, and E each represent an α-amino acid residue, B represents an α-amino acid residue or an α-hydroxy acid residue, and F represents an aminobenzoic acid residue or an aminocycloalkanecarboxylic acid residue. Represents a monovalent group, for example, a hydrogen atom, an amino group, an alkyl group, an alkylene alkyl ether, an alkylene alkyl thioether, an alkylene aldehyde, an alkylene amide, a β-hydroxyamino group, a hydrazide group, an alkoxy group, a thioalkoxy group, Represents an oxy group, an oximato group, an alkylenearyl group, an alkylene ester, an alkylene sulfoxide, or an alkylene sulfone. Another aspect of the invention includes a pharmaceutical composition comprising a compound of Formula (I) and a pharmaceutically acceptable carrier. An additional aspect of the invention is a method of treating a tumor in a mammal, eg, a human, comprising administering to the mammal an effective amount of a compound of Formula (I) in a pharmaceutically acceptable composition. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-4741838-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2006500333-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7851437-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7829531-B2 |
| priorityDate | 1998-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 344.